Last updated: August 1, 2026
Amaryl, the brand name for glimepiride, is a mature second-generation sulfonylurea for type 2 diabetes. Its U.S. market exclusivity has ended, generic glimepiride is widely available, and no active branded clinical development program is driving commercial growth. Future demand is likely to remain stable in cost-sensitive markets but decline as newer therapies, including GLP-1 receptor agonists and SGLT2 inhibitors, replace sulfonylureas in higher-income treatment settings.
What is Amaryl and how does glimepiride work?
Amaryl contains glimepiride, an oral insulin secretagogue in the sulfonylurea class. It lowers blood glucose by stimulating pancreatic beta cells to release insulin. The FDA approved Amaryl for adults with type 2 diabetes as an adjunct to diet and exercise. It can be used as monotherapy or with metformin or insulin when glycemic control is inadequate [1].
The approved product is available primarily as 1 mg, 2 mg, 4 mg and 8 mg tablets. The principal clinical limitation is hypoglycemia, particularly in older adults, patients with impaired renal function, and patients with irregular food intake. Weight gain is also associated with sulfonylurea treatment.
| Product attribute |
Amaryl |
| Active ingredient |
Glimepiride |
| Drug class |
Second-generation sulfonylurea |
| Route |
Oral |
| U.S. approval |
FDA-approved under NDA 020496 |
| Primary indication |
Type 2 diabetes mellitus |
| Dosage forms |
Immediate-release tablets |
| Key safety issue |
Hypoglycemia |
| Originator |
Hoechst Marion Roussel, later associated with Aventis and Sanofi |
| Current U.S. market |
Generic-dominated |
What is the current clinical-trial status of Amaryl?
Amaryl does not have a commercially significant late-stage clinical program. The core evidence base for glimepiride was established before and around its initial approval. Current research is concentrated on comparative effectiveness, combination treatment, cardiovascular outcomes, treatment sequencing and real-world safety rather than registration studies for the Amaryl brand.
ClinicalTrials.gov contains completed and observational studies involving glimepiride, including studies comparing it with metformin, newer oral agents and insulin regimens. These studies generally evaluate glycemic control, hypoglycemia, body weight, treatment persistence or cardiovascular outcomes rather than seek a new indication for branded Amaryl [2].
What clinical evidence supports glimepiride?
Glimepiride lowers glycated hemoglobin in patients with type 2 diabetes, particularly when residual beta-cell function is present. Its low acquisition cost and once-daily dosing remain advantages. Its clinical disadvantages are hypoglycemia and weight gain, which have become more important as treatment guidelines prioritize agents with cardiovascular, renal or weight-loss benefits.
The FDA label reports that glimepiride has been studied in monotherapy and in combination with metformin and insulin. The label also identifies dose-related hypoglycemia and cautions that renal impairment can increase exposure and risk [1].
How does Amaryl compare with newer diabetes drugs?
| Attribute |
Glimepiride |
SGLT2 inhibitors |
GLP-1 receptor agonists |
| Typical role |
Low-cost glucose lowering |
Cardiorenal risk reduction and glucose lowering |
Weight loss, glucose lowering and selected cardiovascular benefit |
| Hypoglycemia risk |
Meaningful, especially with insulin or poor intake |
Low when used without insulin or sulfonylurea |
Low when used without insulin or sulfonylurea |
| Weight effect |
Gain |
Loss or neutral |
Usually loss |
| Oral availability |
Yes |
Yes |
Some oral and injectable products |
| Cost |
Low, generic |
High relative to glimepiride |
High relative to glimepiride |
| Cardiovascular evidence |
Less favorable than newer classes |
Strong for selected outcomes |
Strong for selected outcomes |
| Commercial trend |
Mature or declining |
Expanding |
Expanding |
The American Diabetes Association recommends treatment selection based on cardiovascular disease, heart failure, chronic kidney disease, weight goals, hypoglycemia risk, cost and patient preferences. These criteria tend to favor GLP-1 receptor agonists and SGLT2 inhibitors for higher-risk patients, although low-cost sulfonylureas remain clinically relevant when affordability controls treatment choice [3].
When did Amaryl lose exclusivity?
Amaryl’s U.S. small-molecule exclusivity expired years ago. Generic glimepiride is approved and sold by multiple manufacturers. The product no longer has meaningful U.S. market protection based on brand exclusivity.
The FDA approved Amaryl in 1995. Its regulatory exclusivity and patent protection did not prevent broad generic entry after the applicable protections expired. The brand remains marketed in some jurisdictions, but generic substitution has materially reduced its commercial value in the United States [1,4].
What is the Orange Book status of Amaryl?
The Orange Book identifies Amaryl under NDA 020496. Generic glimepiride products are approved through abbreviated new drug applications. Because glimepiride is an established immediate-release small molecule, generic applicants generally rely on bioequivalence rather than repeat full efficacy trials [4].
The commercial significance of the Orange Book is limited for Amaryl because:
- The product has no active brand-driven exclusivity comparable to a newly approved therapy.
- Generic manufacturers can compete on the same active ingredient and immediate-release dosage form.
- Prescribers and pharmacies can substitute generic glimepiride in accordance with state law and payer policy.
- Any remaining formulation or process patent would need to cover a commercially relevant, listed product feature to delay generic substitution.
The principal market barrier is therefore not FDA exclusivity. It is price competition, distribution access, reimbursement and physician preference.
What patents protect Amaryl and glimepiride?
The original composition-of-matter and product protection for glimepiride has expired. Amaryl is not positioned as a patent-protected growth product in the United States.
| Protection category |
Current commercial relevance |
| Original glimepiride compound protection |
Expired |
| Original Amaryl product protection |
Expired |
| U.S. regulatory exclusivity |
Expired |
| Immediate-release tablet protection |
No meaningful barrier to generic entry |
| Method-of-use patents |
No widely recognized active barrier controlling the core market |
| Manufacturing know-how |
Potentially relevant to cost, purity and supply reliability |
| Brand trademarks |
May protect the Amaryl name but do not block generic glimepiride |
Generic manufacturers may hold process patents, formulation patents or manufacturing know-how in particular jurisdictions. Those rights generally do not recreate the broad exclusivity associated with an active compound patent. They can affect manufacturing economics or specific products but are unlikely to prevent broad generic competition.
Are there Paragraph IV challenges to Amaryl?
Paragraph IV litigation is not a material current risk factor for Amaryl. Paragraph IV certifications are most commercially important when an applicant seeks approval before expiration of a listed patent. Because glimepiride generic entry has already occurred at scale, the main patent dispute window has passed.
The U.S. generic market is instead characterized by multiple approved manufacturers and price competition. Any future litigation would more likely involve a specific formulation, manufacturing process, labeling issue or commercial dispute than a challenge to the basic Amaryl active ingredient.
What is the FDA regulatory status of Amaryl?
Amaryl is an FDA-approved prescription drug for type 2 diabetes. Generic glimepiride tablets are also FDA-approved. No biosimilar pathway applies because glimepiride is a synthetic small molecule, not a biologic.
The regulatory profile is mature:
- The active ingredient has an established safety and efficacy record.
- Generic products rely on abbreviated approval pathways.
- No new branded indication is necessary for continued generic marketing.
- Safety monitoring focuses on hypoglycemia, hypersensitivity, hepatic effects and use in patients with renal or hepatic impairment.
How large is the Amaryl and glimepiride market?
A standalone global revenue figure for Amaryl is not generally disclosed by the originator. Sanofi’s public reporting groups products into broader portfolios, and generic manufacturers typically report glimepiride revenue within larger diabetes or established-products categories.
The addressable disease market is large. The International Diabetes Federation estimated that approximately 537 million adults aged 20 to 79 were living with diabetes in 2021 and projected that the number could reach 783 million by 2045 [5]. Glimepiride competes for a subset of the type 2 diabetes market, primarily patients who require an inexpensive oral agent and can tolerate hypoglycemia risk.
Which regions are most commercially important?
| Region |
Glimepiride outlook |
| United States |
Mature generic market; low brand opportunity |
| Western Europe |
Declining use relative to newer agents; generic pricing |
| Japan and South Korea |
Established use, but competition from newer classes |
| India |
Significant volume opportunity because of diabetes prevalence and affordability |
| China |
Large patient base and generic competition |
| Latin America |
Continued use where treatment cost is a major constraint |
| Middle East and Africa |
Demand supported by access and affordability considerations |
The strongest volume opportunity is in markets where newer agents remain unaffordable or reimbursement is limited. The strongest pricing pressure is also present in those markets because multiple local manufacturers can supply generic tablets.
What is the market projection for Amaryl?
The brand Amaryl is likely to experience flat or declining revenue in developed markets. Generic glimepiride volume can remain resilient, but average selling prices are expected to decline or remain compressed.
Base-case projection
| Period |
Brand Amaryl |
Generic glimepiride |
Main driver |
| 2024-2026 |
Declining |
Stable to modest growth in emerging markets |
Generic substitution and affordability |
| 2027-2029 |
Declining |
Flat to low-single-digit growth by volume |
Diabetes prevalence offset by class migration |
| 2030 onward |
Small branded role |
Mature, price-sensitive market |
GLP-1 and SGLT2 penetration |
A reasonable commercial base case is:
- Branded Amaryl revenue: low-single-digit annual decline in developed markets.
- Generic glimepiride volume: flat to low-single-digit annual growth globally.
- Generic price: continued pressure, particularly in tender-driven markets.
- Market value: flat to declining despite possible unit growth.
- Emerging-market demand: stronger than demand in North America and Western Europe.
The main downside risk is faster substitution by SGLT2 inhibitors, GLP-1 receptor agonists and newer combination products. The main support factor is affordability. Generic glimepiride can remain a treatment option where patients cannot access higher-cost medicines.
How strong is the Amaryl patent estate?
The Amaryl patent estate is weak as a current commercial defense. Its core compound and product protections are expired, and the product is exposed to broad generic competition.
| Patent-strength factor |
Assessment |
| Compound protection |
Very weak or expired |
| Regulatory exclusivity |
None of commercial significance |
| Formulation protection |
Limited for standard immediate-release tablets |
| Method-of-use protection |
Limited market impact |
| Manufacturing barriers |
Possible but generally nonexclusive |
| Generic substitution risk |
High |
| Litigation leverage |
Low |
| Long-term pricing power |
Low |
The most valuable remaining assets are brand recognition, manufacturing quality, regulatory approvals in individual countries and distribution relationships. None provides the economic protection of an active composition-of-matter patent.
What licensing deals and partnerships affect Amaryl?
No current licensing transaction is widely recognized as a major growth driver for Amaryl. Historical commercialization involved the originator’s corporate entities and regional marketing arrangements, but the product’s economic profile is now dominated by generic competition.
Potential commercial activity is more likely to involve:
- Regional generic supply agreements.
- Authorized-generic arrangements.
- Portfolio acquisitions involving established diabetes products.
- Contract manufacturing and distribution.
- Tender participation in public-health systems.
These arrangements can improve market access but do not materially change the patent position.
What generic launch scenarios exist for glimepiride?
The principal generic launch scenario has already occurred. Multiple manufacturers can supply immediate-release glimepiride tablets, and new entrants may compete where regulatory approval and manufacturing economics support entry.
Future generic competition could develop through:
- Lower-cost regional manufacturers.
- New strengths or pack sizes approved under local rules.
- Fixed-dose combinations with metformin.
- Hospital and government procurement contracts.
- Online and retail pharmacy substitution.
A reformulated product could seek differentiation through modified release, adherence packaging or combination therapy, but such products would need to demonstrate a clinical or commercial advantage over inexpensive immediate-release tablets.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest for standard glimepiride tablets. The active ingredient is a mature small molecule, and tablet production uses established technologies. Commercial barriers include:
- Active pharmaceutical ingredient qualification.
- Bioequivalence testing.
- Stability data.
- Good Manufacturing Practice compliance.
- Batch consistency and impurity control.
- Regulatory approval in each target market.
- Reliable low-cost distribution.
Process patents may protect particular synthetic routes or impurity-control methods. They do not generally prevent alternative manufacturing routes. Supply-chain resilience and regulatory compliance are more important than patent exclusivity.
Key Takeaways
- Amaryl is the branded form of glimepiride, a mature sulfonylurea for type 2 diabetes.
- The FDA approved Amaryl in 1995 under NDA 020496.
- Core patent and regulatory protections have expired.
- Generic glimepiride is widely available and creates high substitution risk.
- No active late-stage branded clinical program is driving Amaryl’s market outlook.
- Newer GLP-1 receptor agonists and SGLT2 inhibitors are taking share in higher-income markets.
- Affordability supports continued glimepiride use in India, China, Latin America, Africa and other price-sensitive markets.
- Brand revenue is likely to decline, while generic unit demand should remain stable or grow modestly.
- The patent estate is weak, and manufacturing, reimbursement and distribution are more important than exclusivity.
- Biosimilar risk does not apply because glimepiride is a synthetic small molecule.
FAQs About Amaryl and Glimepiride
Is Amaryl still prescribed in 2025?
Yes. Amaryl and generic glimepiride remain prescribed, particularly when low treatment cost is a priority. Use is more limited in patients at high risk of hypoglycemia or those who would benefit from weight loss or cardiorenal protection.
Is glimepiride safer than glibenclamide?
Glimepiride is generally considered to have a lower hypoglycemia burden than glibenclamide in some clinical settings, but it still carries a meaningful hypoglycemia risk. Individual risk depends on dose, renal function, age, food intake and concurrent therapy.
Does Amaryl have a biosimilar competitor?
No. Biosimilars are used for biologic medicines. Glimepiride is a synthetic small molecule and competes with chemically equivalent generic tablets.
Are there extended-release versions of Amaryl?
The standard Amaryl product is an immediate-release tablet. Any extended-release or modified-release glimepiride product would require separate regulatory support and could face formulation-specific patent and bioequivalence issues.
Can generic glimepiride replace Amaryl automatically?
Pharmacy substitution depends on the product’s regulatory status, state or national law, prescriber instructions and payer policy. FDA-approved generic glimepiride products are intended to be therapeutically equivalent to the corresponding reference product when listed as substitutable in the Orange Book.
References
- U.S. Food and Drug Administration. (2019). Amaryl (glimepiride) prescribing information.
- National Library of Medicine. (n.d.). ClinicalTrials.gov: Glimepiride clinical studies.
- American Diabetes Association Professional Practice Committee. (2024). Standards of care in diabetes - 2024. Diabetes Care, 47(Supplement 1).
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.).
